Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the disease.

Pfizer’s efforts will span small molecule ... for breast cancer – and the BREAKWATER study of BRAF inhibitor Braftovi (encorafenib) as first-line therapy for BRAF-mutated metastatic colorectal ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

The third-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s ... Lorbrena and Braftovi/Mektovi, and as we delivered ...

Lorbrena and Braftovi/Mektovi, and as we delivered on heightened demand for Paxlovid during the recent COVID-19 wave.” For the full fiscal 2024, Pfizer has raised its EPS guidance to a range of ...

Our BRAFTOVI and MEKTOVI combination also -- strong ... a candidate with a differentiated JAK mechanism developed in-house at Pfizer that has the potential to be an expansion of indications ...

Its oncology revenues grew 23% on an operational basis in the first half of 2024, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Seagen’s cancer drugs. Pfizer has ...

Pfizer Inc. (NYSE: PFE) has reported a robust financial performance for the third quarter of 2024, showcasing significant ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year A boost from COVID-19 treatment sales helped bush Pfizer to a ...

Reports Q3 revenue $17.7B, consensus $14.95B. Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We delivered another ...